Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Ischemic Heart Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 129 articles: HTML format Text format

Single Articles

February 2020
1. CAMPBELL BCV, Mitchell PJ, Churilov L, Yassi N, et al
   Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
   JAMA. 2020 Feb 20. pii: 2761799. doi: 10.1001/jama.2020.1511.
   PubMed     Text format     Abstract available
   
   
   
2. MOSLEY JD, Gupta DK, Tan J, Yao J, et al
   Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease.
   JAMA. 2020;323:627-635.
   PubMed     Text format     Abstract available
   
   
   
3. PETERS AT, Mutharasan RK
   Aspirin for Prevention of Cardiovascular Disease.
   JAMA. 2020;323:676.
   PubMed     Text format    
   
   
   
4. ELLIOTT J, Bodinier B, Bond TA, Chadeau-Hyam M, et al
   Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease.
   JAMA. 2020;323:636-645.
   PubMed     Text format     Abstract available
   
   
   
5. KHAN SS, Cooper R, Greenland P
   Do Polygenic Risk Scores Improve Patient Selection for Prevention of Coronary Artery Disease?
   JAMA. 2020;323:614-615.
   PubMed     Text format    
   
   
   
6. DHRUVA SS, Ross JS, Mortazavi BJ, Hurley NC, et al
   Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock.
   JAMA. 2020 Feb 10. pii: 2761003. doi: 10.1001/jama.2020.0254.
   PubMed     Text format     Abstract available
   
   
   January 2020
7. MCEVOY JW, Daya N, Rahman F, Hoogeveen RC, et al
   Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.
   JAMA. 2020;323:329-338.
   PubMed     Text format     Abstract available
   
   
   December 2019
8. YANG WY, Zhang ZY, Staessen JA
   Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomes-Reply.
   JAMA. 2019;322:2343-2344.
   PubMed     Text format    
   
   
   
9. HUANG Y, Kuang J, Mai W
   Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomes.
   JAMA. 2019;322:2342-2343.
   PubMed     Text format    
   
   
   November 2019
10. SLOMSKI A
    Polypill More Effective Than Usual Care for Reducing Cardiovascular Risks.
    JAMA. 2019;322:1948.
    PubMed     Text format    
    
    
    
11. HUFFMAN MD, Salam A, Patel A
    Implementation Strategies for Cardiovascular Polypills.
    JAMA. 2019 Nov 25. pii: 2756238. doi: 10.1001/jama.2019.18102.
    PubMed     Text format    
    
    
    
12. JOYNER MJ, Paneth N
    Cardiovascular Disease Prevention at a Crossroads:: Precision Medicine or Polypill?
    JAMA. 2019 Nov 25. pii: 2756239. doi: 10.1001/jama.2019.19026.
    PubMed     Text format    
    
    
    
13. BAIREY MERZ CN
    Testing for Coronary Microvascular Dysfunction.
    JAMA. 2019 Nov 18. pii: 2755842. doi: 10.1001/jama.2019.16625.
    PubMed     Text format    
    
    
    
14. WEI J, Cheng S, Merz CNB
    Coronary Microvascular Dysfunction Causing Cardiac Ischemia in Women.
    JAMA. 2019 Nov 18. pii: 2755840. doi: 10.1001/jama.2019.15736.
    PubMed     Text format    
    
    
    
15. HONIGBERG MC, Zekavat SM, Aragam K, Finneran P, et al
    Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.
    JAMA. 2019 Nov 18. pii: 2755841. doi: 10.1001/jama.2019.19191.
    PubMed     Text format     Abstract available
    
    
    
16. GOLDBERG AC, Leiter LA, Stroes ESG, Baum SJ, et al
    Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    JAMA. 2019;322:1780-1788.
    PubMed     Text format     Abstract available
    
    
    
17. MEIJERS WC, Moslehi JJ
    Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.
    JAMA. 2019;322:1775-1776.
    PubMed     Text format    
    
    
    
18. WATANABE H, Kimura T
    1 vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention-Reply.
    JAMA. 2019;322:1715-1716.
    PubMed     Text format    
    
    
    
19. TAN WK
    One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention.
    JAMA. 2019;322:1715.
    PubMed     Text format    
    
    
    October 2019
20. HAHN JY, Song YB, Gwon HC
    P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention-Reply.
    JAMA. 2019;322:1607-1608.
    PubMed     Text format    
    
    
    
21. MCCAW ZR, Wei LJ
    P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    JAMA. 2019;322:1607.
    PubMed     Text format    
    
    
    
22. MORRIS NB, Gruss F, Lempert S, English T, et al
    A Preliminary Study of the Effect of Dousing and Foot Immersion on Cardiovascular and Thermal Responses to Extreme Heat.
    JAMA. 2019;322:1411-1413.
    PubMed     Text format    
    
    
    
23. JAIN A, Davis AM
    Primary Prevention of Cardiovascular Disease.
    JAMA. 2019 Oct 4:1-3. doi: 10.1001/jama.2019.15915.
    PubMed     Text format    
    
    
    September 2019
24. WEXLER DJ
    Sulfonylureas and Cardiovascular Safety: The Final Verdict?
    JAMA. 2019 Sep 19. pii: 2751396. doi: 10.1001/jama.2019.14533.
    PubMed     Text format    
    
    
    
25. ROUMIE CL, Chipman J, Min JY, Hackstadt AJ, et al
    Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.
    JAMA. 2019 Sep 19:1-11. doi: 10.1001/jama.2019.13206.
    PubMed     Text format     Abstract available
    
    
    
26. ROSENSTOCK J, Kahn SE, Johansen OE, Zinman B, et al
    Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
    JAMA. 2019 Sep 19. pii: 2751398. doi: 10.1001/jama.2019.13772.
    PubMed     Text format     Abstract available
    
    
    
27. ABBASI J
    Cardiovascular Corner: Prescription Omega-3s, Stroke Rehab, and Statins After Age 75.
    JAMA. 2019 Sep 11. pii: 2751407. doi: 10.1001/jama.2019.14485.
    PubMed     Text format    
    
    
    
28. FERENCE BA, Bhatt DL, Catapano AL, Packard CJ, et al
    Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease.
    JAMA. 2019 Sep 2. pii: 2749533. doi: 10.1001/jama.2019.14120.
    PubMed     Text format     Abstract available
    
    
    
29. AMINIAN A, Zajichek A, Arterburn DE, Wolski KE, et al
    Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity.
    JAMA. 2019 Sep 2. pii: 2749478. doi: 10.1001/jama.2019.14231.
    PubMed     Text format     Abstract available
    
    
    August 2019
30. DUNCAN MS, Freiberg MS, Greevy RA Jr, Kundu S, et al
    Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease.
    JAMA. 2019;322:642-650.
    PubMed     Text format     Abstract available
    
    
    
31. COLE TB
    Smoking Cessation and Reduction of Cardiovascular Disease Risk.
    JAMA. 2019;322:651.
    PubMed     Text format    
    
    
    
32. YANG WY, Melgarejo JD, Thijs L, Zhang ZY, et al
    Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes.
    JAMA. 2019;322:409-420.
    PubMed     Text format     Abstract available
    
    
    
33. ZHONG VW, Van Horn L, Allen NB
    Dietary Cholesterol or Egg Consumption and Cardiovascular Outcomes-Reply.
    JAMA. 2019;322:467.
    PubMed     Text format    
    
    
    
34. KEYSERLING TC, Berkowitz SA, Samuel-Hodge CD
    Dietary Cholesterol or Egg Consumption and Cardiovascular Outcomes.
    JAMA. 2019;322:466-467.
    PubMed     Text format    
    
    
    July 2019
35. JAHAN R, Saver JL, Schwamm LH, Fonarow GC, et al
    Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice.
    JAMA. 2019;322:252-263.
    PubMed     Text format     Abstract available
    
    
    June 2019
36. HAHN JY, Song YB, Oh JH, Chun WJ, et al
    Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    JAMA. 2019;321:2428-2437.
    PubMed     Text format     Abstract available
    
    
    
37. WATANABE H, Domei T, Morimoto T, Natsuaki M, et al
    Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    JAMA. 2019;321:2414-2427.
    PubMed     Text format     Abstract available
    
    
    
38. ABBASI J
    Cardiovascular Corner: Low Lipids, Metformin, and Plant-Based Diets.
    JAMA. 2019 Jun 12. pii: 2736162. doi: 10.1001/jama.2019.6544.
    PubMed     Text format    
    
    
    
39. ZHENG SL, Roddick AJ
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply.
    JAMA. 2019;321:2244-2245.
    PubMed     Text format    
    
    
    
40. SHAH R
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
    JAMA. 2019;321:2244.
    PubMed     Text format    
    
    
    
41. SYN NL, Wee IJY
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
    JAMA. 2019;321:2243-2244.
    PubMed     Text format    
    
    
    May 2019
42. BERRY C, McCartney PJ, Maznyczka AM
    Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction-Reply.
    JAMA. 2019;321:2033-2034.
    PubMed     Text format    
    
    
    
43. ALKHALIL M
    Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction.
    JAMA. 2019;321:2032-2033.
    PubMed     Text format    
    
    
    
44. SEZER M, Umman S
    Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction.
    JAMA. 2019;321:2032.
    PubMed     Text format    
    
    
    
45. CHAN MTV, Wang CY, Seet E, Tam S, et al
    Association of Unrecognized Obstructive Sleep Apnea With Postoperative Cardiovascular Events in Patients Undergoing Major Noncardiac Surgery.
    JAMA. 2019;321:1788-1798.
    PubMed     Text format     Abstract available
    
    
    
46. AUCKLEY D, Memtsoudis S
    Unrecognized Obstructive Sleep Apnea and Postoperative Cardiovascular Complications: A Wake-up Call.
    JAMA. 2019;321:1774-1776.
    PubMed     Text format    
    
    
    
47. WISE RA, Chapman KR, Scirica BM, Bhatt DL, et al
    Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
    JAMA. 2019;321:1693-1701.
    PubMed     Text format     Abstract available
    
    
    
48. 
    Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes.
    JAMA. 2019;321:1720-1721.
    PubMed     Text format    
    
    
    April 2019
49. GREGG EW, Hora I, Benoit SR
    Resurgence in Diabetes-Related Complications.
    JAMA. 2019 Apr 15. pii: 2730953. doi: 10.1001/jama.2019.3471.
    PubMed     Text format    
    
    
    
50. YANO Y, Muntner P, Lloyd-Jones D
    Hypertension in Young Adults and Subsequent Cardiovascular Disease-Reply.
    JAMA. 2019;321:1310-1311.
    PubMed     Text format    
    
    
    
51. DE KOUCHKOVSKY I, Mayfield J, Kohlwes J
    Hypertension in Young Adults and Subsequent Cardiovascular Disease.
    JAMA. 2019;321:1310.
    PubMed     Text format    
    
    
    March 2019
52. ZHONG VW, Van Horn L, Cornelis MC, Wilkins JT, et al
    Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality.
    JAMA. 2019;321:1081-1095.
    PubMed     Text format     Abstract available
    
    
    
53. BONOW RO, Braunwald E
    The Evidence Supporting Cardiovascular Guidelines: Is There Evidence of Progress in the Last Decade?
    JAMA. 2019;321:1053-1054.
    PubMed     Text format    
    
    
    
54. ECKEL RH
    Reconsidering the Importance of the Association of Egg Consumption and Dietary Cholesterol With Cardiovascular Disease Risk.
    JAMA. 2019;321:1055-1056.
    PubMed     Text format    
    
    
    February 2019
55. HANEUSE S, VanderWeele TJ, Arterburn D
    Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies.
    JAMA. 2019;321:602-603.
    PubMed     Text format    
    
    
    January 2019
56. FERENCE BA, Kastelein JJP, Ray KK, Ginsberg HN, et al
    Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
    JAMA. 2019;321:364-373.
    PubMed     Text format     Abstract available
    
    
    
57. NAVAR AM
    The Evolving Story of Triglycerides and Coronary Heart Disease Risk.
    JAMA. 2019;321:347-349.
    PubMed     Text format    
    
    
    
58. ZHENG SL, Roddick AJ
    Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    JAMA. 2019;321:277-287.
    PubMed     Text format     Abstract available
    
    
    
59. MCCARTNEY PJ, Eteiba H, Maznyczka AM, McEntegart M, et al
    Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial.
    JAMA. 2019;321:56-68.
    PubMed     Text format     Abstract available
    
    
    
60. WANG TY, Kaltenbach LA, Cannon CP, Fonarow GC, et al
    Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    JAMA. 2019;321:44-55.
    PubMed     Text format     Abstract available
    
    
    
61. JACKEVICIUS CA, Ko DT
    Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction.
    JAMA. 2019;321:37-39.
    PubMed     Text format    
    
    
    December 2018
62. LOTTA LA, Wittemans LBL, Zuber V, Stewart ID, et al
    Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors.
    JAMA. 2018;320:2553-2563.
    PubMed     Text format     Abstract available
    
    
    
63. WADHERA RK, Joynt Maddox KE, Wasfy JH, Haneuse S, et al
    Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia.
    JAMA. 2018;320:2542-2552.
    PubMed     Text format     Abstract available
    
    
    
64. FONAROW GC
    Unintended Harm Associated With the Hospital Readmissions Reduction Program.
    JAMA. 2018;320:2539-2541.
    PubMed     Text format    
    
    
    
65. SAMIERI C, Empana JP
    Cardiovascular Health and Cognitive Decline-Reply.
    JAMA. 2018;320:2483-2484.
    PubMed     Text format    
    
    
    
66. HOWLAND RH
    Cardiovascular Health and Cognitive Decline.
    JAMA. 2018;320:2483.
    PubMed     Text format    
    
    
    November 2018
67. KIM JM, Stewart R, Yoon JS
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome-Reply.
    JAMA. 2018;320:2152-2153.
    PubMed     Text format    
    
    
    
68. RUST G
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
    JAMA. 2018;320:2152.
    PubMed     Text format    
    
    
    
69. ZIMMERMANN FM, El Farissi M, Tonino PAL
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
    JAMA. 2018;320:2151-2152.
    PubMed     Text format    
    
    
    
70. THOMBS BD, Ziegelstein RC
    Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
    JAMA. 2018;320:2151.
    PubMed     Text format    
    
    
    
71. ROSENSTOCK J, Perkovic V, Johansen OE, Cooper ME, et al
    Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    JAMA. 2018 Nov 9. pii: 2714646. doi: 10.1001/jama.2018.18269.
    PubMed     Text format     Abstract available
    
    
    
72. VAN SLOTEN TT, Tafflet M, Perier MC, Dugravot A, et al
    Association of Change in Cardiovascular Risk Factors With Incident Cardiovascular Events.
    JAMA. 2018;320:1793-1804.
    PubMed     Text format     Abstract available
    
    
    
73. SON JS, Choi S, Kim K, Kim SM, et al
    Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events.
    JAMA. 2018;320:1783-1792.
    PubMed     Text format     Abstract available
    
    
    
74. YANO Y, Reis JP, Colangelo LA, Shimbo D, et al
    Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life.
    JAMA. 2018;320:1774-1782.
    PubMed     Text format     Abstract available
    
    
    
75. VASAN RS
    High Blood Pressure in Young Adulthood and Risk of Premature Cardiovascular Disease: Calibrating Treatment Benefits to Potential Harm.
    JAMA. 2018;320:1760-1763.
    PubMed     Text format    
    
    
    October 2018
76. SLOMSKI A
    No Cardiovascular Protection From Omega-3 Fatty Acids.
    JAMA. 2018;320:1631.
    PubMed     Text format    
    
    
    
77. ABBASI J
    To Prevent Cardiovascular Disease, Pay Attention to Pregnancy Complications.
    JAMA. 2018 Oct 17. pii: 2708197. doi: 10.1001/jama.2018.14645.
    PubMed     Text format    
    
    
    
78. VOELKER R
    Device Approved to Seal Coronary Artery Perforations.
    JAMA. 2018;320:1528.
    PubMed     Text format    
    
    
    
79. FISHER DP, Johnson E, Haneuse S, Arterburn D, et al
    Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity.
    JAMA. 2018;320:1570-1582.
    PubMed     Text format     Abstract available
    
    
    
80. ABBASI J
    Researchers Test New Techniques to Rule Out and Predict Heart Attacks.
    JAMA. 2018;320:1425.
    PubMed     Text format    
    
    
    September 2018
81. BHATT DL
    Fractional Flow Reserve Measurement for the Physiological Assessment of Coronary Artery Stenosis Severity.
    JAMA. 2018;320:1275-1276.
    PubMed     Text format    
    
    
    
82. FRIEDRICH MJ
    Cardiovascular Disease in India.
    JAMA. 2018;320:1097.
    PubMed     Text format    
    
    
    
83. ZHU Y, Zhao Q
    Antiplatelet Therapy After Coronary Artery Bypass Grafting-Reply.
    JAMA. 2018;320:1036-1037.
    PubMed     Text format    
    
    
    
84. SHAH R, Hesterberg K
    Antiplatelet Therapy After Coronary Artery Bypass Grafting.
    JAMA. 2018;320:1035.
    PubMed     Text format    
    
    
    
85. MORI M, Geirsson A
    Antiplatelet Therapy After Coronary Artery Bypass Grafting.
    JAMA. 2018;320:1035-1036.
    PubMed     Text format    
    
    
    
86. WRIGHT JS, Wall HK, Ritchey MD
    Million Hearts 2022: Small Steps Are Needed for Cardiovascular Disease Prevention.
    JAMA. 2018 Sep 6. pii: 2702070. doi: 10.1001/jama.2018.13326.
    PubMed     Text format    
    
    
    August 2018
87. WILLIAMSON W, Lewandowski AJ, Forkert ND, Griffanti L, et al
    Association of Cardiovascular Risk Factors With MRI Indices of Cerebrovascular Structure and Function and White Matter Hyperintensities in Young Adults.
    JAMA. 2018;320:665-673.
    PubMed     Text format     Abstract available
    
    
    
88. SAMIERI C, Perier MC, Gaye B, Proust-Lima C, et al
    Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia.
    JAMA. 2018;320:657-664.
    PubMed     Text format     Abstract available
    
    
    
89. SAVER JL, Cushman M
    Striving for Ideal Cardiovascular and Brain Health: It Is Never Too Early or Too Late.
    JAMA. 2018;320:645-647.
    PubMed     Text format    
    
    
    July 2018
90. DONADINI MP, Bellesini M, Squizzato A
    Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
    JAMA. 2018 Jul 26. pii: 2695067. doi: 10.1001/jama.2018.9641.
    PubMed     Text format     Abstract available
    
    
    
91. KIM JM, Stewart R, Lee YS, Lee HJ, et al
    Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
    JAMA. 2018;320:350-358.
    PubMed     Text format     Abstract available
    
    
    
92. RUBIN R
    Red Meat Allergy Associated With Coronary Artery Plaque.
    JAMA. 2018;320:331.
    PubMed     Text format    
    
    
    
93. JIN J
    Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors.
    JAMA. 2018;320:316.
    PubMed     Text format    
    
    
    
94. WILKINS JT, Lloyd-Jones DM
    USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors: Finding the Right Tests for the Right Patients.
    JAMA. 2018 Jul 10. pii: 2687223. doi: 10.1001/jama.2018.9346.
    PubMed     Text format    
    
    
    
95. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
    Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2018;320:177-183.
    PubMed     Text format     Abstract available
    
    
    
96. LIN JS, Evans CV, Johnson E, Redmond N, et al
    Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2018 Jul 10. pii: 2687224. doi: 10.1001/jama.2018.4242.
    PubMed     Text format     Abstract available
    
    
    
97. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
    Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2018 Jul 10. pii: 2687225. doi: 10.1001/jama.2018.8359.
    PubMed     Text format     Abstract available
    
    
    June 2018
98. SELAK V, Kerr A, Poppe K, Wu B, et al
    Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
    JAMA. 2018;319:2507-2520.
    PubMed     Text format     Abstract available
    
    
    
99. JONAS DE, Reddy S, Middleton JC, Barclay C, et al
    Screening for Cardiovascular Disease Risk With Resting or Exercise Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2018;319:2315-2328.
    PubMed     Text format     Abstract available
    
    
    
100. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
     Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement.
     JAMA. 2018;319:2308-2314.
     PubMed     Text format     Abstract available
     
     
     
101. JIN J
     Screening for Cardiovascular Disease Risk With ECG.
     JAMA. 2018;319:2346.
     PubMed     Text format    
     
     
     
102. MCCARTHY CP, Vaduganathan M, Januzzi JL Jr
     Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment.
     JAMA. 2018 Jun 11. pii: 2684931. doi: 10.1001/jama.2018.7125.
     PubMed     Text format    
     
     
     
103. MERCHANT FM, Dickert NW Jr, Howard DH
     Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests.
     JAMA. 2018 Jun 4. pii: 2683805. doi: 10.1001/jama.2018.6617.
     PubMed     Text format    
     
     
     May 2018
104. BHATT DL
     Percutaneous Coronary Intervention in 2018.
     JAMA. 2018;319:2127-2128.
     PubMed     Text format    
     
     
     
105. ABBASI J
     Another Nail in the Coffin for Fish Oil Supplements.
     JAMA. 2018;319:1851-1852.
     PubMed     Text format    
     
     
     April 2018
106. ZHAO Q, Zhu Y, Xu Z, Cheng Z, et al
     Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
     JAMA. 2018;319:1677-1686.
     PubMed     Text format     Abstract available
     
     
     
107. ALEXANDER JH
     Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes?
     JAMA. 2018;319:1661-1662.
     PubMed     Text format    
     
     
     
108. NAVARESE EP, Robinson JG, Kowalewski M, Kolodziejczak M, et al
     Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
     JAMA. 2018;319:1566-1579.
     PubMed     Text format     Abstract available
     
     
     
109. ABBASI J
     Using Heart Pump Data to Manage Cardiogenic Shock.
     JAMA. 2018;319:1427.
     PubMed     Text format    
     
     
     
110. YU K, Qiu G, Chan KH, Lam KH, et al
     Association of Solid Fuel Use With Risk of Cardiovascular and All-Cause Mortality in Rural China.
     JAMA. 2018;319:1351-1361.
     PubMed     Text format     Abstract available
     
     
     March 2018
111. GUPTA A, Das SR, Pandey A
     beta-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
     JAMA. 2018;319:1269-1270.
     PubMed     Text format    
     
     
     
112. BERWANGER O, Santucci EV, de Barros E Silva PGM, Jesuino IA, et al
     Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
     JAMA. 2018 Mar 11. pii: 2675023. doi: 10.1001/jama.2018.2444.
     PubMed     Text format     Abstract available
     
     
     
113. NICHOLLS SJ, Psaltis PJ
     Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough?
     JAMA. 2018 Mar 11. pii: 2675022. doi: 10.1001/jama.2018.2426.
     PubMed     Text format    
     
     
     
114. ABBASI J
     Do All Patients Need beta-Blockers After a Heart Attack?
     JAMA. 2018;319:853-855.
     PubMed     Text format    
     
     
     February 2018
115. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
     Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.
     JAMA. 2018;319:567-578.
     PubMed     Text format     Abstract available
     
     
     January 2018
116. WADHERA RK, Yeh RW, Joynt Maddox KE
     The Rise and Fall of Mandatory Cardiac Bundled Payments.
     JAMA. 2018;319:335-336.
     PubMed     Text format    
     
     
     
117. KENNEDY AB, Lavie CJ, Blair SN
     Fitness or Fatness: Which Is More Important?
     JAMA. 2018;319:231-232.
     PubMed     Text format    
     
     
     December 2017
118. GREENLAND P
     Cardiovascular Guideline Skepticism vs Lifestyle Realism?
     JAMA. 2017 Dec 14. pii: 2666625. doi: 10.1001/jama.2017.19675.
     PubMed     Text format    
     
     
     November 2017
119. SLOMSKI A
     Evolocumab Reduces Cardiovascular Risk Regardless of Diabetes Status.
     JAMA. 2017;318:1968.
     PubMed     Text format    
     
     
     
120. EMDIN CA, Khera AV, Kathiresan S
     Mendelian Randomization.
     JAMA. 2017;318:1925-1926.
     PubMed     Text format    
     
     
     
121. IRONY TZ
     The "Utility" in Composite Outcome Measures: Measuring What Is Important to Patients.
     JAMA. 2017;318:1820-1821.
     PubMed     Text format    
     
     
     
122. CHAPMAN AR, Lee KK, McAllister DA, Cullen L, et al
     Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.
     JAMA. 2017 Nov 11. doi: 10.1001/jama.2017.17488.
     PubMed     Text format     Abstract available
     
     
     October 2017
123. ABBASI J
     Could a New Method to Detect Coronary Inflammation Prevent Heart Attacks?
     JAMA. 2017;318:1527-1528.
     PubMed     Text format    
     
     
     September 2017
124. WADHERA RK, Bhatt DL
     Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention.
     JAMA. 2017 Sep 28. doi: 10.1001/jama.2017.12087.
     PubMed     Text format    
     
     
     
125. LICHTMAN JH, Jones MR, Leifheit EC, Sheffet AJ, et al
     Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014.
     JAMA. 2017;318:1035-1046.
     PubMed     Text format     Abstract available
     
     
     
126. BARNARD ND, Willett WC, Ding EL
     The Misuse of Meta-analysis in Nutrition Research.
     JAMA. 2017 Sep 18. doi: 10.1001/jama.2017.12083.
     PubMed     Text format    
     
     
     
127. DEVEREAUX PJ, Biccard BM, Chan MTV
     High-Sensitivity Troponin Levels, Ischemia, and Mortality-Reply.
     JAMA. 2017;318:865.
     PubMed     Text format    
     
     
     
128. SMILOWITZ NR
     High-Sensitivity Troponin Levels, Ischemia, and Mortality.
     JAMA. 2017;318:864-865.
     PubMed     Text format    
     
     
     August 2017
129. KRUMHOLZ HM
     Treatment of Cholesterol in 2017.
     JAMA. 2017;318:417-418.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: